@article{article, title  = {{Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)}},

 publisher = {{Wiley}},

 url = {{}},

 year = {{2021}},

 month = {{3}},

 author = {{Wollenberg A and Blauvelt A and Guttman‐Yassky E and Worm M and Lynde C and Lacour J and Spelman L and Katoh N and Saeki H and Poulin Y and Lesiak A et al}},

 doi = {{10.1111/bjd.19574}},

 volume = {{184}},

 journal = {{British Journal of Dermatology}},

 issue = {{3}},

 pages = {{437-449}},

 note = {{Accessed on 2025/11/05}}}